Covid-19 roundup: Alex­ion's C5 in­hibitor Ul­tomiris miss­es the PhI­II bar; Lon­za in wait­ing game to use in­gre­di­ents in Mod­er­na vac­cine

C5 in­hi­bi­tion isn’t the an­swer to the search for treat­ments for se­vere Covid-19 af­ter all.

Alex­ion is paus­ing en­roll­ment to a Phase III study test­ing Ul­tomiris, the long-act­ing fol­low-on to Soliris, among pa­tients re­quir­ing me­chan­i­cal ven­ti­la­tion af­ter the in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee raised a lack of ef­fi­ca­cy in an in­ter­im analy­sis. Among 122 pa­tients (out of a planned en­roll­ment of 270), there was no mean­ing­ful dif­fer­ence in sur­vival at Day 29.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.